520

LEAN, OVERWEIGHT AND OBESE MASLD PATIENTS HAVE SIMILAR AMOUNTS OF FIBROSIS THAT IS ASSOCIATED WITH POLYGENIC RISK

Date
May 19, 2024
Explore related products in the following collection:

Loading...

Tracks

Related Products

Thumbnail for MASLD For the Non-Hepatologist
MASLD For the Non-Hepatologist
RISK STRATIFICATION IN REFERRALS FOR MASLD: GI ASSESSMENT
Thumbnail for ALT, FIBROSCAN VCTE, AND FIBROSCAN CAP AS PREDICTIVE MARKERS OF RESMETIROM BIOPSY RESPONSE
ALT, FIBROSCAN VCTE, AND FIBROSCAN CAP AS PREDICTIVE MARKERS OF RESMETIROM BIOPSY RESPONSE
INTRODUCTION. MAESTRO-NASH (NCT03900429) is an ongoing 54-month, randomized, double-blind, placebo-controlled Phase 3 trial evaluating the efficacy of resmetirom in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and fibrosis…